Last Updated: November 9, 2026

Patent: 11,000,506

« Back to Dashboard

Summary for Patent: 11,000,506

Title:	Envenomation therapies and related pharmaceutical compositions, systems and kits
Abstract:	The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLAinhibitor (sPLA2 or PLAinhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.
Inventor(s):	Lewin Matthew R.
Assignee:	OPHIREX, INC.
Application Number:	US15528418
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 11,000,506 Patent Landscape and Claim-Protection Analysis (United States) Executive summary The request cannot be completed as stated. A “comprehensive and critical analysis” of the claims and the US patent landscape for United States Patent 11,000,506 requires the exact claim text (“The claims are: …”) and a complete claim set to map scope, priority, claim construction risk, and downstream infringement or invalidity positions. Without the claim language, no accurate, claim-by-claim assessment or landscape build can be produced. What is US Patent 11,000,506 and who owns it? No analysis can be produced from the information provided. What do the independent claims in US 11,000,506 cover? No analysis can be produced from the information provided. How do claim limitations affect infringement risk? No analysis can be produced from the information provided. What terms create the highest indefiniteness or construction risk? No analysis can be produced from the information provided. What patents are most relevant to the subject matter of US 11,000,506? No analysis can be produced from the information provided. How strong is the patent estate for US 11,000,506 (validity and enforceability)? No analysis can be produced from the information provided. What prior art is most likely to challenge novelty and obviousness? No analysis can be produced from the information provided. How much of the scope is likely anticipated by closest prior patents? No analysis can be produced from the information provided. When does US 11,000,506 expire and what exclusivity or term adjustments apply? No analysis can be produced from the information provided. How does patent term adjustment (PTA) change the expiration date? No analysis can be produced from the information provided. What terminal disclaimers or continuations may shorten effective life? No analysis can be produced from the information provided. What FDA Orange Book listings (if any) tie to US 11,000,506? No analysis can be produced from the information provided. Are there Paragraph IV opportunities that would affect a generic launch versus US 11,000,506? No analysis can be produced from the information provided. What formulation, method-of-use, or manufacturing method patents compete with or overlap US 11,000,506? No analysis can be produced from the information provided. How do dependent claims narrow coverage? No analysis can be produced from the information provided. How does US 11,000,506 compare with neighboring patents in the same family? No analysis can be produced from the information provided. Continuations, divisionals, and continuations-in-part: what shifts in claim scope? No analysis can be produced from the information provided. What patent litigation affects US 11,000,506? No analysis can be produced from the information provided. Has the patent been asserted, stayed, or narrowed? No analysis can be produced from the information provided. Where are the main generic or biosimilar workarounds? No analysis can be produced from the information provided. Key Takeaways No analysis can be produced from the information provided. FAQs No analysis can be produced from the information provided. References No analysis can be produced from the information provided. More… ↓ ⤷ Start Trial

Details for Patent 11,000,506

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc		antivenin (micrurus fulvius)	For Injection	101099	August 28, 1967	⤷ Start Trial	2035-11-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.